Risperdal Lawsuit News: $2.2 Billion Federal Settlement Was Pennsylvania’s Largest Qui Tam Case, Ber

The Firm is representing numerous Risperdal lawsuit clients who allegedly developed gynecomastia (male breast growth) due to their use of the atypical antipsychotic medication. New York, New York (PRWEB) November 12, 2014 As the litigation involving Risperdal and gynecomastia (http://www.risperdallawsuit2014.com/risperdal-gynecomastia/) continues to grow, Bernstein Liebhard LLP notes that last year’s landmark $2.2 billion settlement between the manufacturers of the drug and the federal government was Pennsylvania’s largest involving a qui tam, or whistleblower case. A recent analysis of co
Contributor
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations